# SRZN earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SRZN) · [Earnings tab](https://www.lopjlb.com/stock/SRZN?tab=earnings)

Updated: 2026-11-06T07:25:19

Quarters analyzed: 1

## Cross-quarter narrative

Surrozen's 2022 Q4 call provided the first detailed update on its two lead Phase I programs, SZN-043 for alcoholic hepatitis and SZN-1326 for ulcerative colitis. Management disclosed that both programs had experienced transaminase elevations, prompting a temporary dosing pause. The company has since resumed dosing using a Minimum Anticipated Biological Effect Level (MABEL) approach to mitigate safety risks. Financially, Surrozen reported a cash runway extending into the second half of 2024, providing visibility beyond the near-term clinical readouts. A partnered milestone with Boehringer Ingelheim, valued at $10 million, is expected to be achieved by year-end 2023. The tone of prepared remarks was moderately positive (mgmt tone 0.6), emphasizing progress despite the safety interruption, while guidance remained vague and uncertainty was assessed at 0.50. No specific revenue, margin, or demand metrics were discussed, consistent with a pre-revenue clinical-stage biotech. The call introduced several key themes: clinical progress amid safety management, dosing strategy adaptation, cash runway clarity, and partnered milestone execution. No prior calls are available for comparison, so all themes appear as new developments in this initial snapshot. No fears or delays were explicitly flagged beyond the transaminase elevations that have already been addressed via the MABEL dosing resumption.

## Latest CallCard · Q4

Surrozen updates Phase I programs SZN-043 (alcoholic hepatitis) and SZN-1326 (UC) after transaminase elevations; resuming with MABEL dosing; cash runway into H2 2024; Boehringer $10M milestone by year-end 2023.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Prepared remarks emphasize progress on both lea

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2022 Q4:** Surrozen updates Phase I programs SZN-043 (alcoholic hepatitis) and SZN-1326 (UC) after transaminase elevations; resuming with MABEL dosing; cash runway into H2 2024; Boehringer $10M milestone by year-end 2023.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Prepared remarks emphasize progress on both lea

## Theme arcs

- **Clinical development progress (SZN-043, SZN-1326)** (new): First update on both Phase I programs; transaminase elevations noted, dosing resumed with MABEL strategy.
- **Safety monitoring and risk mitigation** (new): Transaminase elevations identified; MABEL dosing implemented to manage tolerability.
- **Dosing strategy optimization** (new): Adoption of MABEL dosing for both programs after safety pause.
- **Cash runway visibility** (new): Runway projected into H2 2024.
- **Partnership milestone execution (Boehringer Ingelheim)** (new): $10M milestone expected by year-end 2023.

## Fear persistence

- **Safety/tolerability (transaminase elevations)** [new]: Transaminase elevations observed in both Phase I programs, leading to temporary dosing pause; addressed via MABEL dosing resumption.

## Guidance path

2022 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SRZN`